Chinese healthcare-focused GP HighLight Capital is set to exit its position in US-based biotechnology company Bonti after Allergan agreed to acquire the business for $195 million, plus additional payments if certain development targets are met.
KKR has agreed to pay INR4.3 billion ($59.6 million) to South African hospital chain Life Healthcare Group for its stake in Max Healthcare, a hospital operator that it owns through a joint venture with Max India.
Wuxi AppTec, a contract pharmaceutical R&D services provider backed by several private equity investors, has filed for a Hong Kong listing less than four months after listing in Shanghai. The size and pricing of the IPO have yet to be decided, but the...
Hong Kong Asia Medical, a privately-owned Chinese cardiology hospital operator, has received a $150 million investment from General Atlantic amid escalating interest from global investors toward China’s biotech and healthcare industry.
The Overseas Private Investment Corporation (OPIC), a development finance arm of the US government, has committed $150 million to Quadria Capital II, the latest fund of healthcare-focused PE firm Quadria Capital.
Healthcare specialist GTJA Investment Group leads a $130 million Series B for Jianke in the expectation that the company will consolidate its leadership position in China's online pharmacy market
Weimai, a Chinese healthcare-focused big data platform that operates on a city-by-city basis, has received $30 million in Series B funding led by Cenova Ventures, Source Code Capital, Vision Plus Capital, and Matrix Partners China.
China Renaissance Holdings is planning an aggressive push into wealth management services, targeting high net worth individuals in China’s new economy, with proceeds from its upcoming Hong Kong IPO.
Chinese online pharmacy operator 111 Inc – best known for its 1 Drugsstore platform – traded down slightly on its NASDAQ debut after raising $100.5 million in a scaled back IPO.
The Carlyle Group has paid an undisclosed sum for a significant minority stake in Ambio, a US-based pharmaceuticals company with substantial operations in China.
Chinese online pharmacy operator Jianke has closed a $130 million Series B funding round led by healthcare-focused GTJA Investment Group.
Indian online drug marketplace operator Netmeds has received a $45 million Series C funding round with participation from Russian venture capital investor Sistema Asia Fund.
Chinese drug maker Jacobio has secured a $55 million Series C funding round led by Qiming Venture Partners and Hillhouse Capital, with participation from Prudence Investment Management.
Adamantem Capital has agreed to buy Australia-based Zenitas Healthcare in a deal worth approximately A$122 million ($88 million), including debt. It is working with Liverpool Partners, an investment and advisory firm with extensive experience in healthcare.
Vietnam’s VinaCapital has launched a $100 million VC unit and confirmed its first two domestic investments. Separately, the private equity firm has committed $25 million to a local hospital operator.
Harbour BioMed, a China-based biopharmaceutical company focused on treatments for cancer and autoimmune disorders, has raised an $85 million Series B round led by Singapore’s GIC Private.
China Biologic Products, a US-listed biopharmaceuticals player that was subject to two take-private offers, said it was set to raise $590 million by issuing new shares to investors including Centurium Capital, CITIC Capital, and Hillhouse Capital.
GL Capital, a healthcare-focused GP based in China, has invested GBP9.75 million ($12.5 million) in UK-listed health technology platform Oxford BioDynamics (OBD) as part of a larger partnership aimed at expansion in China.
Mabpharm, a China-based biopharmaceutical company backed by CDH Investments, has filed for an IPO in Hong Kong, the latest in a growing number of proposed listings under new rules that allow biotech companies with no revenue or profits to go public.
Sequoia Capital India has closed its sixth fund at $695 million, surpassing a target range of $625-675 million.
Ascentage Pharma, a Chinese biopharmaceutical company with several private equity backers, has filed for an IPO in Hong Kong.
US-listed China Biologic Products has received a buyout offer worth $3.9 billion from a consortium including former CEO David Gao and CDH Investments. It follows a $3.6 billion bid last month by CITIC Capital.
Matrix Partners has raised $300 million for its third India-focused venture capital fund, which will back companies in sectors including consumer and enterprise technology and financial technology.
Chinese online pharmacy operator 111 Inc, which counts ClearVue Partners, Verlinvest and BioVeda Capital among its investors, has filed for an IPO in the US.